Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies
作者: Stephan ArnoldVincent BadalamentiAnyzeila DiazTeresa GasallaCindy McSheaJohn WhitesidesToufic Fakhoury
作者单位: 1Neurozentrum Nymphenburg, Romanstr. 93, 80639, München, Germany
2Schön Klinik Vogtareuth, Krankenhausstraße 20, 83569, Vogtareuth, Germany
3UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617,, USA
4UCB Pharma,1950 Lake Park Drive, Smyrna, GA 30080, USA
5UCB Pharma, Alfred-Nobel-Strasse 10, 40789, Monheim am Rhein, Germany
6Saint Joseph Hospital, One Saint Joseph Drive, Lexington, KY 40504, USA
刊名: Epilepsy Research, 2018, Vol.141 , pp.73-82
来源数据库: Elsevier Journal
DOI: 10.1016/j.eplepsyres.2018.02.005
关键词: Focal seizuresAntiepileptic drugBrivaracetamMonotherapyEfficacyTolerability
原始语种摘要: Abstract(#br)Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) approved for monotherapy (in the USA) and adjunctive treatment of focal (partial-onset) seizures in adults, at a dose range of 50–200 mg/day taken in two equal doses, with a recommended starting dose of 100 mg/day. Two Phase III, randomized, double-blind, multicenter, historical-controlled, conversion-to-monotherapy studies (N01276, NCT00698581; N01306, NCT00699283) were conducted to evaluate the efficacy, safety, and tolerability of conversion to BRV 50 mg/day monotherapy in adults with uncontrolled focal seizures. Patients aged 16–75 years, with 2–40 focal seizures per 4 weeks during an 8-week baseline, and on stable doses of 1–2 AEDs were enrolled....
全文获取路径: Elsevier  (合作)
影响因子:2.241 (2012)

  • multicenter 多中心性
  • monotherapy 硫化物
  • focal 焦点的
  • historical 历史的
  • treatment 处理
  • control 控制
  • antiepileptic 镇痫剂
  • cumulative 累积的
  • efficacy 效验
  • tapering 渐狭的